PE20090423A1 - Compuestos moduladores de sirtuina - Google Patents
Compuestos moduladores de sirtuinaInfo
- Publication number
- PE20090423A1 PE20090423A1 PE2008001057A PE2008001057A PE20090423A1 PE 20090423 A1 PE20090423 A1 PE 20090423A1 PE 2008001057 A PE2008001057 A PE 2008001057A PE 2008001057 A PE2008001057 A PE 2008001057A PE 20090423 A1 PE20090423 A1 PE 20090423A1
- Authority
- PE
- Peru
- Prior art keywords
- thiazol
- imidazo
- phenyl
- compounds
- carboxamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000011990 Sirtuin Human genes 0.000 title abstract 2
- 108050002485 Sirtuin Proteins 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical class OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 abstract 1
- LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical class CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WOBNLJFCDCDKFA-UHFFFAOYSA-N morpholinomethyl Chemical class [CH2]N1CCOCC1 WOBNLJFCDCDKFA-UHFFFAOYSA-N 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- CGJMVNVWQHPASW-UHFFFAOYSA-N quinoxaline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CN=C21 CGJMVNVWQHPASW-UHFFFAOYSA-N 0.000 abstract 1
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663307P | 2007-06-20 | 2007-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090423A1 true PE20090423A1 (es) | 2009-04-18 |
Family
ID=39810276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001057A PE20090423A1 (es) | 2007-06-20 | 2008-06-20 | Compuestos moduladores de sirtuina |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7829556B2 (enExample) |
| EP (1) | EP2167510B1 (enExample) |
| JP (1) | JP5281081B2 (enExample) |
| KR (1) | KR101525268B1 (enExample) |
| CN (1) | CN101874031B (enExample) |
| AR (1) | AR067106A1 (enExample) |
| AU (1) | AU2008266746B2 (enExample) |
| BR (1) | BRPI0813653A2 (enExample) |
| CA (1) | CA2692099C (enExample) |
| CL (1) | CL2008001821A1 (enExample) |
| CO (1) | CO6261382A2 (enExample) |
| CR (1) | CR11231A (enExample) |
| DO (1) | DOP2009000283A (enExample) |
| EA (1) | EA018182B1 (enExample) |
| ES (1) | ES2534544T3 (enExample) |
| IL (1) | IL202729A (enExample) |
| MA (1) | MA31568B1 (enExample) |
| MX (1) | MX2009013976A (enExample) |
| MY (1) | MY149316A (enExample) |
| NZ (1) | NZ581989A (enExample) |
| PE (1) | PE20090423A1 (enExample) |
| TW (1) | TW200918542A (enExample) |
| UA (1) | UA104127C2 (enExample) |
| UY (1) | UY31170A1 (enExample) |
| WO (1) | WO2008156866A1 (enExample) |
| ZA (1) | ZA200908882B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| EP1853610A1 (en) * | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| ES2397275T3 (es) | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
| US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| TW200918542A (en) * | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| WO2009099643A1 (en) * | 2008-02-07 | 2009-08-13 | The J. David Gladstone Institutes | Use of sirt1 activators or inhibitors to modulate an immune response |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| EA021938B1 (ru) * | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| CN104193740A (zh) | 2008-07-03 | 2014-12-10 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 |
| RU2519779C2 (ru) | 2008-09-29 | 2014-06-20 | Сертрис Фармасьютикалз Инк. | Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| AU2009333588A1 (en) | 2008-12-08 | 2011-07-21 | Northwestern University | Method of modulating HSF-1 |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US20110054569A1 (en) * | 2009-09-01 | 2011-03-03 | Zitnik Ralph J | Prescription pad for treatment of inflammatory disorders |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| JP2013509442A (ja) | 2009-10-29 | 2013-03-14 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節因子としての二環式ピリジンおよび類似体 |
| EP2496594B1 (en) * | 2009-11-06 | 2018-01-17 | The J. David Gladstone Institutes | Methods and compositions for modulating tau levels |
| US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) * | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| WO2011079309A2 (en) | 2009-12-23 | 2011-06-30 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| JP6038773B2 (ja) | 2010-04-15 | 2016-12-07 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン活性化因子および活性化アッセイ |
| CN107988228B (zh) * | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
| WO2011143317A2 (en) * | 2010-05-11 | 2011-11-17 | President And Fellows Of Harvard College | Methods for the regulation of cellular metabolism through the modulation of sirt3 activity |
| DK2670404T3 (en) | 2011-02-02 | 2018-11-19 | Univ Princeton | CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| EP2968333B1 (en) | 2013-03-15 | 2022-01-12 | NuSirt Sciences, Inc. | Leucine and nicotinic acid for the reduction of lipid levels |
| WO2015002892A1 (en) * | 2013-07-01 | 2015-01-08 | Meier Joshua Abraham | Methods of treating diseases by modulating mitochondrial dna deletions |
| SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
| JP2017518306A (ja) | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用 |
| KR20170008320A (ko) | 2014-06-06 | 2017-01-23 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도 |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| KR101839688B1 (ko) | 2015-08-21 | 2018-03-19 | 중앙대학교 산학협력단 | 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도 |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017123161A1 (en) * | 2016-01-15 | 2017-07-20 | Agency For Science, Technology And Research | Inhibition of intracellular growth of mycobacterium species and its applications |
| EP3405107B1 (en) | 2016-01-20 | 2023-04-12 | Setpoint Medical Corporation | Control of vagal stimulation |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTIVE CHARGING SYSTEMS |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| CN109475572A (zh) | 2016-02-22 | 2019-03-15 | 宾夕法尼亚州大学信托人 | 用于增强肝再生的方法 |
| US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| CN109700790A (zh) * | 2018-12-28 | 2019-05-03 | 中南大学湘雅医院 | 一种靶向AQP3的抗皮肤衰老药物Butein |
| CN113939334A (zh) | 2019-04-12 | 2022-01-14 | 赛博恩特医疗器械公司 | 迷走神经刺激来处理神经退行性障碍 |
| CN111000854B (zh) * | 2019-12-30 | 2023-06-09 | 昆药集团股份有限公司 | 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用 |
| KR20230012585A (ko) | 2020-05-21 | 2023-01-26 | 더 파인스타인 인스티튜츠 포 메디칼 리서치 | 미주 신경 자극을 위한 시스템들 및 방법들 |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| KR20250039366A (ko) * | 2022-06-17 | 2025-03-20 | 코다젠 바이오사이언시스 인코포레이티드 | 시르투인 활성화 화합물을 포함하는 시르투인 조절 화합물, 및 이의 응용 |
| US12012370B1 (en) | 2022-12-29 | 2024-06-18 | Codagen Biosciences, Inc. | Sirtuin modulating compounds and applications thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
| US3517007A (en) | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| ZA735753B (en) | 1972-09-14 | 1974-07-31 | American Cyanamid Co | Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles |
| US4018932A (en) | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| JPH0576084A (ja) | 1991-09-11 | 1993-03-26 | Matsushita Electric Ind Co Ltd | 遠隔表示装置 |
| JPH05289689A (ja) | 1992-04-06 | 1993-11-05 | Sanyo Electric Co Ltd | 可搬性規則音声合成装置 |
| JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔２，１−ｂ〕チアゾール誘導体 |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| US8354397B2 (en) | 2001-07-27 | 2013-01-15 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| HUP0103986A2 (hu) | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| HUP0103987A3 (en) | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| JP2005298333A (ja) | 2001-11-15 | 2005-10-27 | Meiji Seika Kaisha Ltd | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 |
| DE602004015429D1 (de) | 2003-03-11 | 2008-09-11 | Pfizer Prod Inc | Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf) |
| EP1605967A1 (en) | 2003-03-13 | 2005-12-21 | Novo Nordisk A/S | Novel nph insulin preparations |
| WO2005058884A2 (en) | 2003-12-15 | 2005-06-30 | Japan Tobacco Inc. | Cyclopropane compounds and pharmaceutical use thereof |
| WO2005069998A2 (en) | 2004-01-20 | 2005-08-04 | Brigham Young University Technology Transfer Office | Novel sirtuin activating compounds and methods for making the same |
| RU2445095C2 (ru) | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
| AU2005257883A1 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
| EP1819341A4 (en) | 2004-11-10 | 2011-06-29 | Synta Pharmaceuticals Corp | IL-12 MODULATORY CONNECTIONS |
| EP1853610A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| BRPI0608910A2 (pt) | 2005-05-09 | 2010-02-17 | Achillion Pharmaceuticals Inc | uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| ES2397275T3 (es) | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
| TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| CN101910184A (zh) | 2007-11-08 | 2010-12-08 | 西特里斯药业公司 | 可溶性噻唑并吡啶 |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-06-19 TW TW097122811A patent/TW200918542A/zh unknown
- 2008-06-19 CL CL2008001821A patent/CL2008001821A1/es unknown
- 2008-06-20 KR KR1020107000398A patent/KR101525268B1/ko not_active Expired - Fee Related
- 2008-06-20 PE PE2008001057A patent/PE20090423A1/es active IP Right Grant
- 2008-06-20 MY MYPI20095422A patent/MY149316A/en unknown
- 2008-06-20 ES ES08768696.0T patent/ES2534544T3/es active Active
- 2008-06-20 NZ NZ581989A patent/NZ581989A/en not_active IP Right Cessation
- 2008-06-20 CA CA2692099A patent/CA2692099C/en not_active Expired - Fee Related
- 2008-06-20 MX MX2009013976A patent/MX2009013976A/es active IP Right Grant
- 2008-06-20 UA UAA201000211A patent/UA104127C2/ru unknown
- 2008-06-20 BR BRPI0813653-0A2A patent/BRPI0813653A2/pt not_active Application Discontinuation
- 2008-06-20 UY UY31170A patent/UY31170A1/es not_active Application Discontinuation
- 2008-06-20 EA EA201070034A patent/EA018182B1/ru not_active IP Right Cessation
- 2008-06-20 CN CN2008801034489A patent/CN101874031B/zh not_active Expired - Fee Related
- 2008-06-20 EP EP08768696.0A patent/EP2167510B1/en active Active
- 2008-06-20 AU AU2008266746A patent/AU2008266746B2/en not_active Ceased
- 2008-06-20 WO PCT/US2008/007771 patent/WO2008156866A1/en not_active Ceased
- 2008-06-20 JP JP2010513266A patent/JP5281081B2/ja not_active Expired - Fee Related
- 2008-06-20 US US12/214,804 patent/US7829556B2/en not_active Expired - Fee Related
- 2008-06-20 AR ARP080102662A patent/AR067106A1/es unknown
-
2009
- 2009-12-11 DO DO2009000283A patent/DOP2009000283A/es unknown
- 2009-12-14 ZA ZA200908882A patent/ZA200908882B/xx unknown
- 2009-12-14 IL IL202729A patent/IL202729A/en not_active IP Right Cessation
-
2010
- 2010-01-08 CO CO10001888A patent/CO6261382A2/es active IP Right Grant
- 2010-01-15 MA MA32518A patent/MA31568B1/fr unknown
- 2010-01-20 CR CR11231A patent/CR11231A/es unknown
- 2010-09-27 US US12/891,667 patent/US8247565B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
| PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| EA200702498A1 (ru) | N-(пиридин-2-ил)сульфонамидные производные | |
| PE20091065A1 (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| EA201290255A1 (ru) | Способы и композиции для лечения рака | |
| ATE384058T1 (de) | Thiazolderivate | |
| EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| EA201000702A1 (ru) | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы | |
| EA200700099A1 (ru) | Производные пиридина | |
| EA200801997A1 (ru) | Новые соединения | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| MX2013008213A (es) | N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| PE20091092A1 (es) | Compuestos heterociclicos como inhibidores de la via hedgehog | |
| ATE442349T1 (de) | Diacylglycerol-acyltransferase-hemmer | |
| EA201070483A1 (ru) | Новые офтальмологические композиции | |
| EA201001414A1 (ru) | Производные азетидина и их применение | |
| ATE522526T1 (de) | 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen | |
| EA201070018A1 (ru) | Замещенные 2-[2-(фенил)этиламино] алканамидные производные и применение указанных соединений в качестве модуляторов натриевых и/или кальциевых каналов | |
| ATE528306T1 (de) | Benzoxazepin-verbindungen, ihre herstellung und verwendung | |
| EA200801011A1 (ru) | Производные пиразина как модуляторы натриевых каналов для лечения боли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |